Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBIT (2021 - 2025)

Historic EBIT for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $44.3 million.

  • Krystal Biotech's EBIT rose 699.7% to $44.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $161.1 million, marking a year-over-year increase of 14513.99%. This contributed to the annual value of $161.3 million for FY2025, which is 14532.31% up from last year.
  • Krystal Biotech's EBIT amounted to $44.3 million in Q4 2025, which was up 699.7% from $41.4 million recorded in Q3 2025.
  • Krystal Biotech's EBIT's 5-year high stood at $44.3 million during Q4 2025, with a 5-year trough of -$50.2 million in Q1 2022.
  • Its 5-year average for EBIT is -$4.8 million, with a median of -$15.0 million in 2021.
  • Per our database at Business Quant, Krystal Biotech's EBIT plummeted by 24990.59% in 2022 and then soared by 117386.08% in 2024.
  • Krystal Biotech's EBIT (Quarter) stood at -$21.9 million in 2021, then crashed by 58.95% to -$34.8 million in 2022, then skyrocketed by 109.34% to $3.2 million in 2023, then skyrocketed by 1173.86% to $41.4 million in 2024, then increased by 7.0% to $44.3 million in 2025.
  • Its last three reported values are $44.3 million in Q4 2025, $41.4 million for Q3 2025, and $39.3 million during Q2 2025.